Clinical significance of serum SP-D as a biomarker for antifibrotics in idiopathic pulmonary fibrosis (IPF): Post hoc analysis of a phase 3 trial of pirfenidone in Japan
H. Chiba (Sapporo, Japan), . Ikeda (Sapporo, Japan), A. Azuma (Tokyo, Japan), Y. Kondoh (Seto, Japan), T. Ogura (Yokohama, Japan), Y. Taguchi (Tenri, Japan), M. Ebina (Sendai, Japan), S. Miyazawa (Osaka, Japan), H. Sakaguchi (Osaka, Japan), M. Suga (Kumamoto, Japan), Y. Sugiyama (Shimotsuke, Japan), T. Nukiwa (Sendai, Japan), S. Kudoh (Tokyo, Japan), H. Takahashi (Sapporo, Japan)
Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Chiba (Sapporo, Japan), . Ikeda (Sapporo, Japan), A. Azuma (Tokyo, Japan), Y. Kondoh (Seto, Japan), T. Ogura (Yokohama, Japan), Y. Taguchi (Tenri, Japan), M. Ebina (Sendai, Japan), S. Miyazawa (Osaka, Japan), H. Sakaguchi (Osaka, Japan), M. Suga (Kumamoto, Japan), Y. Sugiyama (Shimotsuke, Japan), T. Nukiwa (Sendai, Japan), S. Kudoh (Tokyo, Japan), H. Takahashi (Sapporo, Japan). Clinical significance of serum SP-D as a biomarker for antifibrotics in idiopathic pulmonary fibrosis (IPF): Post hoc analysis of a phase 3 trial of pirfenidone in Japan. 2249
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: